**S10 Fig. Sensitivity Network Meta-Analysis for Abstinence at the End of Treatment and Dropout at the End of Treatment by Considering only the Trials on Individuals Addicted to Cocaine and no other Stimulant.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CBT** | 1.07(0.66, 1.74) | 1.14(0.64, 2.01) | **0.41****(0.21, 0.78)** | 0.75(0.23, 2.41) | 0.53(0.26, 1.09) | 0.92(0.34, 2.45) | 2.40(0.78, 7.34) | 1.13(0.62, 2.04) | 0.96(0.52, 1.77) | 1.44(0.99, 2.10) | 1.61(0.93, 2.81) | 1.88(0.63, 5.58) |
| **0.45****(0.28,0.73)** | **CM** | 1.06(0.63, 1.76) | **0.38****(0.20, 0.71)** | 0.70(0.22, 2.23) | 0.50(0.23, 1.06) | 0.85(0.32, 2.26) | 2.23(0.72, 6.95) | 1.05(0.70, 1.58) | 0.89(0.44, 1.82) | 1.34(0.88, 2.05) | 1.50(0.79, 2.87) | 1.75(0.59, 5.17) |
| **0.46****(0.27, 0.77)** | 1.02(0.61, 1.70) | **CM+CBT** | **0.36****(0.17, 0.77)** | 0.66(0.19, 2.27) | 0.47(0.20, 1.09) | 0.81(0.28, 2.34) | 2.11(0.63, 7.05) | 0.99(0.54, 1.82) | 0.84(0.38, 1.88) | 1.27(0.71, 2.28) | 1.42(0.67, 3.01) | 1.66(0.52, 5.27) |
| **0.38****(0.17, 0.84)** | 0.84(0.40, 1.77) | 0.83(0.35, 1.96) | **CM+CRA** | 1.84(0.69, 4.89) | 1.31(0.73, 2.34) | **2.25****(1.07, 4.72)** | **5.88****(1.73, 19.91)** | **2.77****(1.32, 5.78)** | **2.35****(1.01, 5.43)** | **3.54****(1.91, 6.54)** | **3.96****(1.81, 8.67)** | **4.61****(1.91, 11.14)** |
| 0.58(0.13, 2.52) | 1.29(0.30, 5.49) | 1.27(0.28, 5.73) | 1.53(0.44, 5.29) | **CM +12step** | 0.71(0.23, 2.20) | 1.22(0.47, 3.20) | 3.20(0.67, 15.25) | 1.50(0.44, 5.11) | 1.28(0.35, 4.62) | 1.92(0.61, 6.09) | 2.15(0.62, 7.53) | 2.51(0.93, 6.74) |
| 0.52(0.18, 1.48) | 1.15(0.40, 3.36) | 1.13(0.37, 3.50) | 1.37(0.53, 3.55) | 0.89(0.19, 4.25) | **CRA** | 1.72(0.68, 4.38) | **4.49****(1.25, 16.15)** | 2.11(0.91, 4.89) | 1.79(0.72, 4.45) | **2.70****(1.31, 5.58)** | **3.03****(1.28, 7.17)** | **3.52****(1.25, 9.97)** |
| 0.85(0.23, 3.14) | 1.90(0.53, 6.81) | 1.86(0.48, 7.17) | 2.25(0.79, 6.36) | 1.47(0.39, 5.50) | 1.64(0.40, 6.73) | **CRA+ NCR** | 2.61(0.63, 10.87) | 1.23(0.43, 3.49) | 1.04(0.34, 3.19) | 1.57(0.60, 4.11) | 1.76(0.60, 5.17) | 2.05(0.83, 5.07) |
| 0.54(0.15, 1.98) | 1.21(0.33, 4.43) | 1.18(0.31, 4.58) | 1.43(0.34, 6.05) | 0.93(0.14, 6.24) | 1.04(0.21, 5.31) | 0.64(0.11, 3.77) | **MBT** | 0.47(0.14, 1.56) | 0.40(0.12, 1.35) | 0.60(0.21, 1.73) | 0.67(0.21, 2.19) | 0.78(0.17, 3.53) |
| 1.31(0.72, 2.38) | **2.93****(1.89, 4.55)** | **2.88****(1.54, 5.39)** | **3.48****(1.50, 8.07)** | 2.27(0.51, 10.13) | 2.54(0.82, 7.88) | 1.55(0.41, 5.89) | 2.43(0.63, 9.36) | **NCR** | 0.85(0.38, 1.89) | 1.28(0.73, 2.25) | 1.43(0.68, 3.01) | 1.67(0.53, 5.25) |
| 1.15(0.55, 2.41) | **2.56****(1.13, 5.83)** | **2.52****(1.05, 6.02)** | **3.04****(1.08, 8.54)** | 1.98(0.40, 9.94) | 2.22(0.63, 7.82) | 1.35(0.31, 5.86) | 2.13(0.50, 9.03) | 0.87(0.36, 2.13) | **SEPT** | 1.51(0.82, 2.78) | 1.69(0.87, 3.26) | 1.97(0.58, 6.61) |
| 1.11(0.73, 1.67) | **2.48****(1.65, 3.73)** | **2.43****(1.40, 4.22)** | **2.93****(1.39, 6.19)** | 1.91(0.45, 8.12) | 2.15(0.75, 6.17) | 1.31(0.36, 4.69) | 2.05(0.60, 7.07) | 0.84(0.49, 1.44) | 0.97(0.46, 2.04) | **TAU** | 1.12(0.66, 1.90) | 1.30(0.45, 3.81) |
| 0.89(0.54, 1.46) | **1.99****(1.07, 3.70)** | 1.96(0.99, 3.85) | 2.36(0.98, 5.70) | 1.54(0.34, 7.03) | 1.72(0.55, 5.36) | 1.05(0.27, 4.10) | 1.65(0.43, 6.33) | 0.68(0.33, 1.38) | 0.78(0.36, 1.67) | 0.80(0.48, 1.36) | **12step** | 1.16 (0.36,3.78) |
| 1.49(0.35, 6.33) | 3.34(0.81, 13.79) | 3.28(0.75, 14.39) | **3.96****(1.18, 13.24)** | 2.58(0.63, 10.55) | 2.89(0.62, 13.44) | 1.76(0.45, 6.84) | 2.77(0.42, 18.17) | 1.14(0.26, 4.95) | 1.30(0.27, 6.37) | 1.35(0.33, 5.57) | 1.68(0.38, 7.46) | **12step+ NCR** |

Psychosocial treatment Abstinence at the end of treatment (OR [95% Cl]) Dropout due to any cause at the end of treatment (OR [95% Cl])

**Notes**. Psychosocial treatments are reported in alphabetical order. Comparisons should be read from left to right. The “abstinence at 12 weeks” and the “dropout due to any cause at 12 weeks “ estimates are located at the intersection of the column-defining treatment and the row-defining treatment. For abstinence, an OR above 1 favors the column-defining treatment. For dropout due to any cause, an OR above 1 favors the row-defining treatment. To obtain ORs for comparisons in the opposing direction, reciprocals should be taken. Significant results are in bold and underlined. CBT: cognitive behavioural therapy; CM: contingency management; CRA: community reinforcement approach; MBT: meditation based therapies; NCR: not contingent rewards; SEPT: supportive expressive psychodynamic therapy; TAU: treatment as usual; 12 step: twelve-step programme.